

Thursday, April 16, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Lisa Hunt, R.Ph.

Kort Delost, R.Ph.

Elizabeth Young, Pharm.D.

Ellie Brownstein, M.D.

Clinton Sheffield, M.D.

Julia Ozbolt, M.D.

Committee Members Excused:

Beth Johnson, R.Ph.

Jameson Rice, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Trevor Smith, CPhT

Merelynn Berrett, RN

Heather Santacruz, RN

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, UofU

Other Individuals Present:

James McAdams, Orexo

Sushma Patel, AstraZeneca

Rob Bingham, Shire

Charissa Anne, J&J

Cody Ball, Select Health

Devin Stuck, UofU

Mellanie Wallentine, DMHF

Julie McDavitt, BI

Kelly Ponce, AstraZeneca

Kim Cooponi, AstraZeneca

Laura Litzenberger, Janssen

Candice Nielson, UofU

Meeting conducted by: Kort Delost

1. **Review and Approval of March Minutes:** Meeting minutes for March were reviewed. Elizabeth Young made a motion to approve the minutes, Kort Delost seconded the motion. All in favor.
2. **Housekeeping:**
 - a. Lisa Hunt said that North Dakota and Vermont will join the purchasing pool which would increase the purchasing power for potential supplemental rebates.
 - b. Lisa Hunt introduced Dr. Clinton Sheffield. He will replace Dr. Julia Ozbolt in the next meeting and thanked her for her willingness to serve on the P&T committee.

3. **Drug Utilization Review (DUR) Board update:** The DUR board reviewed Afrezza, inhaled insulins in the April 2015 meeting. For May, the DUR board is planning to review allergy treatments, Grastek, Ragwitek and Oralair.
4. **PRISM Announcement** – Melanie Wallentine from the UDOH PRISM claims processing system, which is currently under development, passed out materials requesting providers to perform testing of the new system. She said that anyone interested can email prism@utah.gov with questions or to ask about testing opportunities.
5. **Opens Meeting Act Annual Training** – Postposed until next meeting
6. **Board Business** –
 - a. Lisa Hunt asked if there was interest in making a nomination for a new P&T Committee Chairperson. The board decided that the nomination and election would be postponed because of the members absent from the April meeting. Ellie Brownstein made a motion to postpone the nomination until next month. Kort Delost seconded the motion.
 - b. Lisa Hunt presented the P&T committee training information for committee members. She said asked for disclosure statements to be filled out, and any contact information updates. She offered to answer any questions about the training materials.
7. **SGLT-2 Inhibitors** – Melissa Archer presented a review of the SGLT-2 Inhibitor agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
8. **Other States Report** - Lisa Hunt presented information from other States, with their Preferred Drug List listings for the SGLT-2 drug class.
9. **Public Comments:**
 - a. Julia McDavitt (BI, *Jardiance, Glyxambi*) - She presented information about Jardiance and Glyxambi and offered to answer questions from the board.
 - b. Laura Litzenburger (Janssen, *Invokana, Invokamet*) - She presented information about Invokana and Invokamet and offered to answer questions from the board.
 - c. Sushma Patel (AstraZeneca, *Farxiga, Xigduo*) - She presented information about Farxig and Xigduo and offered to answer questions from the board.
10. **Committee discussion:**
 - a. Kort Delost asked about any risk for kidney problems through the use of the SGLT-2 drugs. Melissa Archer said that there is a risk for bladder cancer, but no known risks for kidney problems. She said that for patients with current kidney problems, the drugs could pose a problem.
 - b. Kort Delost asked about insulin and what effects it would have when used with

the drug. He was answered that there is an increased risk of hypoglycemia, which can be compensated for by dose adjustments of the SGLT-2 or the insulin.

- c. Clinton Sheffield asked if there are endpoints in the SGLT-2 studies other than A1-C. He was answered that there are none published studies currently, but there are cardiovascular studies in process.
- d. Kort Delost asked about how many people stop the medications because of the genital mycotic infections or urinary tract infections. He was answered that only about 1% discontinue because of these infections.
- e. Julia Ozbolt asked if the committee is going to review both the single agents and the combination agents. Lisa Hunt responded that they are both under review today and are to be discussed for inclusion on the PDL. They will be voted upon separately.
- f. Kort asked if these agents are all second line for treatment. Melissa Archer answered that they would be second line unless there is a contraindication to first line agents.
- g. Ellie Brownstein made a motion that the single agents are equally safe and efficacious for inclusion on the PDL. Clinton Sheffield seconded the motion. All in favor.
- h. Julia Ozbolt said that the combination agents can increase compliance.
- i. Lisa Hunt said that Utah Medicaid will look at costs after safety and efficacy are decided. She said that sometimes the Utah Medicaid will pay for two single agents instead of a combination if there is an economic benefit to the State.
- j. Committee discussion about the combination agents containing different products and including them in the same PDL class would not be good in this case. Two of the products are combined with metformin, and one is a DPP-4 with SGLT-2. The committee decided that the agents could be included in separate classes on the PDL.
- k. Kort Delost said that the SGLT-2 agents in combination with metformin are equally safe and effective. Julia Ozbolt seconded the motion. All in favor.
- l. Kort Delost made a motion that the DPP-4 and SGLT-2 combination agent is safe and efficacious to include on the PDL. Clinton Sheffield seconded the motion. All in favor.

11. **Meeting Adjourned** – Ellie Brownstein made a motion to close the meeting. Julia Ozbolt seconded the motion. All in favor. Meeting Adjourned

12. Next meeting is scheduled for May 21, 2015. Hepatitis C combination agents, agents to treat angina and the annual training will be discussed.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov